- Imara Inc (NASDAQ:IMRA) has agreed to divest tovinontrine (IMR-687) and all other assets related to its PDE9 program to Cardurion Pharmaceuticals Inc.
- In addition to $250,000 previously paid by Cardurion upon execution of a non-binding term sheet, the aggregate purchase price consists of an upfront payment of $34.75 million and $60 million as milestone payments.
- In case of termination, the company would be obligated to pay a fee of $1.5 million Cardurion.
- In April, Imara posted interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (SCD) and Forte Phase 2b trial in beta-thalassemia.
- No meaningful benefit was observed in transfusion burden in either tovinontrine group compared to the placebo in the beta-thalassemia study.
- Imara announced discontinuing the Ardent and Forte trials and further developing tovinontrine in sickle cell disease and beta-thalassemia.
- Price Action: IMRA shares are up 37.60% at $1.61 during the premarket session on the last check Wednesday.
AbbVie vs Coherus: Dispute Emerges over Upcoming Launch of Low-Cost Biosimilar, Yusimry
AbbVie Inc (NYSE: ABBV) has challenged Coherus BioSciences Inc (NASDAQ: CHRS), alleging Coherus breached its settlement and license agreement after it announced its plans to launch Yusimry, a biosimilar of
